TY - JOUR
T1 - Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
AU - Le Coutre, Philipp
AU - Ottmann, Oliver G.
AU - Giles, Francis
AU - Kim, Dong Wook
AU - Cortes, Jorge
AU - Gattermann, Norbert
AU - Apperley, Jane F.
AU - Larson, Richard A.
AU - Abruzzese, Elisabetta
AU - O'Brien, Stephen G.
AU - Kuliczkowski, Kazimierz
AU - Hochhaus, Andreas
AU - Mahon, Francois Xavier
AU - Saglio, Giuseppe
AU - Gobbi, Marco
AU - Kwong, Yok Lam
AU - Baccarani, Michele
AU - Hughes, Timothy
AU - Martinelli, Giovanni
AU - Radich, Jerald P.
AU - Zheng, Ming
AU - Shou, Yaping
AU - Kantarjian, Hagop
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2008/2/15
Y1 - 2008/2/15
N2 - Patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia (CML-AP) have very limited therapeutic options. Nilotinib is a highly selective BCR-ABL tyrosine kinase inhibitor. This phase 2 trial was designed to characterize the efficacy and safety of nilotinib (400 mg twice daily) in this patient population with hematologic response (HR) as primary efficacy endpoint. A total of 119 patients were enrolled and had a median duration of treatment of 202 days (range, 2-611 days). An HR was observed in 56 patients (47%; 95% confidence interval [CI], 38%-56%). Major cytogenetic response (MCyR) was observed in 35 patients (29%; 95% CI, 21%-39%). The median duration of HR has not been reached. Overall survival rate among the 119 patients after 12 months of follow-up was 79% (95% CI, 70%-87%). Nonhematologic adverse events were mostly mild to moderate. Severe peripheral edema and pleural effusions were not observed. The most common grade 3 or higher hematologic adverse events were thrombocytopenia (35%) and neutropenia (21%). Grade 3 or higher bilirubin and lipase elevations occurred in 9% and 18% of patients, respectively, resulting in treatment discontinuation in one patient. In conclusion, nilotinib is an effective and well-tolerated treatment in imatinib-resistant and -intolerant CML-AP. This trial is registered at www.clinicaltrials. gov as NCT00384228.
AB - Patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia (CML-AP) have very limited therapeutic options. Nilotinib is a highly selective BCR-ABL tyrosine kinase inhibitor. This phase 2 trial was designed to characterize the efficacy and safety of nilotinib (400 mg twice daily) in this patient population with hematologic response (HR) as primary efficacy endpoint. A total of 119 patients were enrolled and had a median duration of treatment of 202 days (range, 2-611 days). An HR was observed in 56 patients (47%; 95% confidence interval [CI], 38%-56%). Major cytogenetic response (MCyR) was observed in 35 patients (29%; 95% CI, 21%-39%). The median duration of HR has not been reached. Overall survival rate among the 119 patients after 12 months of follow-up was 79% (95% CI, 70%-87%). Nonhematologic adverse events were mostly mild to moderate. Severe peripheral edema and pleural effusions were not observed. The most common grade 3 or higher hematologic adverse events were thrombocytopenia (35%) and neutropenia (21%). Grade 3 or higher bilirubin and lipase elevations occurred in 9% and 18% of patients, respectively, resulting in treatment discontinuation in one patient. In conclusion, nilotinib is an effective and well-tolerated treatment in imatinib-resistant and -intolerant CML-AP. This trial is registered at www.clinicaltrials. gov as NCT00384228.
UR - http://www.scopus.com/inward/record.url?scp=41349083969&partnerID=8YFLogxK
U2 - 10.1182/blood-2007-04-083196
DO - 10.1182/blood-2007-04-083196
M3 - Article
C2 - 18048643
AN - SCOPUS:41349083969
VL - 111
SP - 1834
EP - 1839
JO - Blood
JF - Blood
SN - 0006-4971
IS - 4
ER -